RVTY Stock Chart & Stats
$1910.00
$0.00(0.00%)
At close: 4:00 PM EDT
$1910.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,644.85 - $2,235.19
Previous CloseN/A
Volume0.00
Average Volume (3M)3.00
Market Cap
$245.75B
Enterprise Value$15.02K
Total Cash (Recent Filing)$1.02B
Total Debt (Recent Filing)$3.34B
Price to Earnings (P/E)60.5
Beta-0.08
Next Earnings
Nov 02, 2026EPS Estimate
21.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.10
Shares Outstanding111,586,400
10 Day Avg. Volume0
30 Day Avg. Volume3
Financial Highlights & Ratios
PEG Ratio-3.41
Price to Book (P/B)1.52
Price to Sales (P/S)3.85
P/FCF Ratio21.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$2,132.63Price Target Upside11.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)90.58
Revenue Forecast (FY)$48.23B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationStrong current operating and free cash flow gives Revvity internal funding for product development, acquisitions, debt reduction, and customer support. Because cash generation is well supported by earnings, it can reinforce resilience and strategic flexibility over the next several quarters.
Diagnostics GrowthDiagnostics is showing meaningful organic momentum across reproductive health and immunodiagnostics, providing a growth engine while other areas are softer. Broad demand across testing programs can support recurring workflow sales and improve the company’s mix over the next several quarters.
Manageable LeverageManageable leverage and a sizable equity base reduce balance-sheet strain and preserve financial flexibility. This supports continued investment in laboratory products and services while helping Revvity absorb normal fluctuations in customer capital spending without excessive balance-sheet pressure.
Bears Say
Margin CompressionProfitability remains positive, but margins are well below prior-cycle levels, indicating that recent revenue momentum has not fully restored historical earnings quality. Sustained compression could limit operating leverage, reduce reinvestment capacity, and make long-term earnings more sensitive to execution.
Life Sciences And Software WeaknessWeakness in Life Sciences and the sharp Signals decline show that growth is uneven across Revvity’s portfolio. Contract timing and difficult comparisons may improve, but continued volatility could delay software scaling, weaken near-term visibility, and offset stronger Diagnostics performance.
China Portfolio TransitionThe planned China immunodiagnostics divestiture addresses a structurally difficult market but creates a multi-period portfolio transition. Until closing, the business remains in reported results, while approvals and execution could prolong complexity and leave geographic mix changes unresolved.
Revvity News
RVTY FAQ
What was Revvity’s price range in the past 12 months?
Revvity lowest stock price was $1644.85 and its highest was $2235.19 in the past 12 months.
What is Revvity’s market cap?
Revvity’s market cap is $245.75B.
When is Revvity’s upcoming earnings report date?
Revvity’s upcoming earnings report date is Nov 02, 2026 which is in 53 days.
How were Revvity’s earnings last quarter?
Revvity released its earnings results on Aug 04, 2026. The company reported $23.846 earnings per share for the quarter, beating the consensus estimate of $20.531 by $3.315.
Is Revvity overvalued?
According to Wall Street analysts Revvity’s price is currently Undervalued.
Does Revvity pay dividends?
Revvity does not currently pay dividends.
What is Revvity’s EPS estimate?
Revvity’s EPS estimate is 21.9.
How many shares outstanding does Revvity have?
Revvity has 111,586,400 shares outstanding.
What happened to Revvity’s price movement after its last earnings report?
Revvity reported an EPS of $23.846 in its last earnings report, beating expectations of $20.531. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Revvity?
Currently, no hedge funds are holding shares in MX:RVTY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Revvity Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2,132.63 (11.66% Upside)
$2,132.63 (11.66% Upside)
Blogger Sentiment
Neutral
MX:RVTY Sentiment 75%
Sector Average 60%
Sector Average 60%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.69%
12-Months-Change
Fundamentals
Return on Equity
0.22%
Trailing 12-Months
Asset Growth
-2.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Revvity
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
RVTY Company Deck
RVTY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.View all MX:RVTY earnings summariesRVTY Revenue Breakdown
50.11% Life sciences
49.89% Diagnostics
RVTY Stock 12 Month Forecast
Average Price Target
$2,132.63
▲(11.66% Upside)